Scripps Research Unveils Pol-theta's Active Structure, Advancing Cancer Drug Development

Scientists at Scripps Research have captured the first detailed images of polymerase theta (Pol-theta) in its active state, providing crucial insights into how this enzyme repairs DNA in cancer cells. The study, published in Nature Structural & Molecular Biology reveals Pol-theta's structural changes when binding to broken DNA strands, offering a blueprint for developing more targeted cancer treatments. 

Pol-theta, an enzyme involved in cell repair, is particularly important in cancers with BRCA1 or BRCA2 mutations, such as certain breast and ovarian cancers. These cancers rely on Pol-theta's error-prone DNA repair method when more accurate repair mechanisms are compromised.

Using cryo-electron microscopy and biochemical experiments, the research team discovered that Pol-theta switches from a tetrameric to a dimeric configuration when binding to broken DNA strands. This active state enables Pol-theta to repair DNA through a two-step process: first, searching for matching sequences called "microhomologies" on broken strands, then holding these strands together for repair without requiring additional energy.

The study's findings are significant for cancer treatment development. As Pol-theta is produced at low levels in healthy cells but is crucial for cancer cell survival, it presents a promising target for therapies that could potentially have fewer side effects than current treatments.

While drugs inhibiting Pol-theta are already in clinical trials, this new understanding of the enzyme's structure and function could lead to more effective and precise treatments. The research team, led by Gabriel Lander, aims to further investigate Pol-theta's tetrameric form and its interactions with other DNA repair enzymes, potentially uncovering new approaches to targeting BRCA-associated cancers.